ÃâÒßѧÊÔÌâ
"3Y0`&:D Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£©
o?Oc7$+u 1. Fas(CD95)/FasL
uQKT 2. common chain of cytokine receptor
a9Zq{Ysj 3 . TCR/CD3 complex
.8JTe0 4. negaive selection of thymocytes
am6L8N 5. artificial active immune
;Q`lNFa 6. anti-idiotypic
\Yr Ue1 7. IgSF
s6`?LZ0(z 8. Integrin
JNnDts*w 9. chemokine
e~"U @8xk~ 10. B7/CD28
:?1Dko^ ¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²60·Ö£©
'PW5ux@`< 1. ±È½ÏMHC¢ñºÍMHC¢òÀ࿹ԲÎÓëµÄ¼Ó¹¤Ìá³Ê¿¹ÔµÄ¹ý³Ì¡£
E}Uc7G 2. ±È½ÏCTLºÍNKɱÉ˰Ðϸ°ûʱʶ±ðºÍɱÉË»úÖÆµÄÌØµã¡£
+]{G@pn
3. ±È½ÏÃâÒßѧ¼ì²â·¨ºÍÉúÎïѧ»îÐÔ¼ì²â·¨¼ì²âϸ°ûÒò×ÓµÄÓÅȱµã¡£ 4. ·¢ÏÖÒ»ÖÖеİ×ϸ°û·Ö»¯¿¹Ô»òÖ×ÁöÏà¹Ø¿¹Ô,²¢ÖƱ¸Á˵¥¿Ë¡¿¹Ìå,ÊÔÉè¼ÆÊµÑé·½°¸¿Ë¡´Ë»ùÒò¡£
S)"Jf? 5. Ñ¡ÔñÏÂÊöÖÐÒ»¸öרÌâ,ÐðÊöÎÒ¹úÔÚÕâÒ»Ñо¿ÁìÓòµÄÏÖ×´¼°ÃæÁÙµÄÌôÕ½
tw)mep
wB
Q\sK"~@3 1)Ö×ÁöÃâÒߣ»(2)»ùÒòÖÎÁÆ£»(3)CD¿¹Ô¡£
m+z&
Q µÚËľüÒ½´óѧһ¾Å¾ÅÆßÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÃâÒßѧÊÔÌâ
+k R4E23: Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£©
nQ3A~ () 1. B7/CD28
<<O$ G7c 2. Th1 subset
-jmY)(\ 3. seven predicated transmembrane domain receptor superfamily£¨STR superfamily£©
B&"Q\'c 4. antibody affinity maturation
y$M%2
mh` 5. AP-1
\cM2k- 6. single chain variable fragment£¨ScFv£©
%
|L=l{g 7. NK cell receptor
E2+`4g@{8< 8. Zinkernagel-Doherty phenomenon
&mM0AA'\?H 9. Ig fold
W[r>.7>?h 10. CD40/CD40L
P[fq8lDA ¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²36·Ö£©
$<[79al# 1. ÊÔÊöÐØÏÙ΢»·¾³¶ÔÐØÏÙϸ°ûµÄÑ¡Ôñ×÷Óü°ÆäÓëTϸ°û¹¦ÄÜÐÔÑÇȺÐγɵĹØÏµ¡£
*lJxH8 \ 2. ÊÔÊöÌåÒºÃâÒßÓ¦´ðµÄ¹æÂÉ£¬»ØÒä·´Ó¦ºÍ¿¹ÌåÀà±ðת»»µÄ»úÖÆÊÇʲô£¿
bpa?C 3. ÊԴӽṹºÍ¹¦ÄܵȽǶȣ¬²ûÊö°×ϸ°û·Ö»¯¿¹Ô£¨CD£©¡¢Õ³¸½·Ö×Ó£¨integrin£©ºÍÃâÒßÇòµ°°×³¬¼Ò×壨IgSF£©ÈýÀà·Ö×ÓµÄÏ໥¹ØÏµ¡£Ä¿Ç°ÔÚÕâÒ»ÁìÓòÖÐÖ÷ÒªÑо¿ÈȵãÊÇʲô£¿
'dc#F3 Èý. ÎÊ´ðÌ⣨24·Ö£¬µÚ1ÌâΪÃâÒßѧרҵ¿¼ÉúÊÔÌ⣬µÚ2ÌâΪѪҺ²¡Ñ§¿Æ¿¼ÉúÊÔÌ⣬µÚ3ÌâΪÏû»¯ÄÚ¿Æ¿¼ÉúÊÔÌ⣬ֻÔÊÐí´ð±¾×¨ÒµÊÔÌ⣩
7_[L o4_ 1. ÊԱȽÏTCRºÍBCR½á¹¹¼°Æäʶ±ð¿¹Ô¡¢ÁܰÍϸ°û»î»¯ÐźŵķÖ×Ó»úÀí¡££¨ÃâÒßѧרҵ£©¡£
9+!hg'9Qn 2. ÊÔÊö°×Ѫ²¡ÃâÒßѧ·ÖÐÍÀíÂۺͷ½·¨µÄÑо¿½øÕ¹¡££¨ÑªÒº²¡Ñ§×¨Òµ£©¡£
/G`]=@~ 3. ÊÔÊöÖ×ÁöÒßÃçµÄÑо¿½øÕ¹¡££¨Ïû»¯ÄÚ¿Æ×¨Òµ£©¡£
Y}KNKO; Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ
`XDl_E+>l £¨ÃâÒßѧרҵºÍרҵ»ù´¡£©
*qpSXmOz Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£©
-trkA'ewZ 1.Co-stimulators (or co-stimulating molecules)
0<*<$U 2.NK-kB
?Z} &EH 3.Immunoglobulin superfamily
\z ) %$#I 4.antigen-presenting cell (APC)
?gXp*>Kg[ 5.death domain
X5w$4Kj&4l 6.CCR and CXCR
asqV~
n 7.Lectin (or mitogen)
>8[Z.fX 8.Clusters of differentiation, CD)
V28M lP 9.B7 family
z0Z%m@ 10.Cytotoxic T lymphocyte, CTL)
5~S5F3 11.IL-15 and IL-15 receptor (IL-15R)
?&uu[y 12.MHC restriction
EiaW1Cs 13.Affinity-chromatography
dgP
3@`YS 14.Cyctosprin A, CsA
uEx-]F 15.Antibody-dependent cell-mediated cytotoxicity, ADCC)
?r!o~|9| ¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£©
"EJ~QCW*Yh 1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿
%]7d`/ 2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£
Kf-JcBsrT 3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹ÔµÄÌØµã¡£
(QiAisE Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£©
UL9n-M= ÃâÒßѧרҵ£º
;O#>Y 1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£
Zgb!E]V[ Ïû»¯ÄÚ¿Æ£º
L4
l!96]a 2.Ö×Áö¿¹Ô·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£
EEL,^3KR ѪҺ²¡Ñ§×¨Òµ£º
~bpgSP" 3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔÒò£¨Ìõ¼þ£©ÊÇʲô£¿
\.}c9*) Ò»¾Å¾ÅÄê¾Å²©Ê¿ÉúÈëѧ¿¼ÊÔÊÔÌâ
Wn}'bqp (רҵ»ù´¡: ÃâÒßѧ)
YA5g';$H* Ò».Ãû´Ê½âÊÍ(ÿÌâ5·Ö,¹²45·Ö)
[1H^3g
' 1. ADCC(antibody dependent cell-mediated cytotoxicity)
\lNN Msd& 2. »·æß¾úËØ(cyclosporin)
-H-~;EzU 3. KIR(killer cell inhibitory receptor)
rQ snhv 4. HLDA(human leucocyte differentiation antigen)
>c}u>]D 5. Interleukin 18(IL-18)
H" 7u7l 6. ÕûºÏËØ(integrin)
/z $u]X 7. Fas/FasL
XRQ4\bMA8 8. FcR(ÃâÒßÇòµ°°×Fc¶ÎÊÜÌå)
3HK\BS 9. ϸ°û¼äÕ³¸½·Ö×Ó(ICAM)
|! "eWTJ 10. Th1/Th2
|
VDV<g5h 11. »ùÒòÒßÃç(DNAÒßÃç)
Y\'}a+:@Ph 12. chemokines and chemokine receptor
Fv`,3aNB 13. ÃâÒßÄÍÊÜ
"tpSg 14. ¹²´Ì¼¤·Ö×Ó
eb$#A _m 15. ËÀÍö½á¹¹Óò(death domain)
1[-tD0{H ¶þ.ÎÊ´ðÌâ(µÚ1¡¢2Ìâ¸÷18·Ö,µÚ3Ìâ19·Ö)
IMONgFBS 1. ÊԱȽÏɱÉËÐÔTϸ°û(CTL)Óë×ÔȻɱÉËϸ°û(NK)ÔÚɱÉ˰Ðϸ°û¹ý³ÌÖÐ,ʶ±ðϸ°û¶¾¼°½éµ¼ÃâÒß¹¦ÄÜÓкβ»Í¬?
+X]vl=0 2. 70Äê´úÒÔÀ´,ÓйØIgºÍÌåÒºÃâÒßÑо¿´æÔÚÒÔϼ¸ÏîÖØ´ó·¢ÏÖºÍÍ»ÆÆ¶ø»ñµÃҽѧºÍÉúÎïѧŵ±´¶û½±,Çë·Ö±ð²ûÊöËüÃǵÄÀíÂÛÒâÒå¼°ÔÚҽѧʵ¼ùÖеÄÓ¦Óá£
.(2ik5A%9 £¨1£©1972Ä꣺θµ°°×øºÍľ¹Ïµ°°×øˮ½âIg£¬»ñµÃFab¡¢Fc¡¢F£¨ab¡¯£©2µÈƬ¶Î
)dd@\n$6 £¨2£©1977Ä꣺·ÅÉäÃâÒß·¨
lks!w/yCF £¨3£©1984Ä꣺ÁܰÍϸ°ûÔÓ½»ÁöºÍµ¥¿Ë¡¿¹Ìå
d m%8K6| £¨4£©1987Äê: Ig»ùÒòµÄ½á¹¹
RViuJ; 3. ½üÄêÀ´ÔÚÖ×ÁöÃâÒßÑо¿ÁìÓòÖÐÓÐÄÄÐ©ÖØÒª½øÕ¹?ÊÔÊöµ±Ç°Ìá¸ß»úÌ忹Ö×ÁöÃâÒßµÄÖ÷Òª²ßÂÔ¡£
"g8M0[7e3 Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(ÃâÒßѧרҵ)
sCHJ&>m5- ÎÊ´ðÌâ(ÿÌâ25·Ö)
[}]Q?*_ 1. ÊԱȽÏTϸ°ûÊÜÌ壨TCR£©¡¢Bϸ°ûÊÜÌ壨BCR£©ºÍNKϸ°ûÊÜÌ壨NKCR£©µÄ×é³É£¬Ê¶±ðÅäÌåÒÔ¼°ÐźÅתµ¼µÄÒìͬµã¡£
GWip
-wI 2. ÒÔÐØÏÙÒÀÀµ¿¹Ô´Ì¼¤»úÌå²úÉú¿¹ÌåµÄÃâÒßÓ¦´ðΪÀý£¬Tϸ°ûºÍBϸ°ûÊÇÈçºÎÏ໥×÷Óã¿ÓÐÄÄЩճ¸½·Ö×Ӻ͹²´Ì¼¤·Ö×Ó²ÎÓëT¡¢Bϸ°ûµÄÏ໥×÷Óã¿
+=8VTCn? 3. Éö×ÛºÏÕ÷³öѪÈÈ(HFRS)²¡¶¾µÄ½á¹¹»ùÒòÒѾ¸ãÇå³þ,ΪÁË֤ʵHFRS²¡¶¾¸ÐȾ»úÌå(ÒÔBalb/CСÊóΪÀý)¿É²úÉúHFRS²¡¶¾ºËÒ¿ǵ°°×(NP)ÌØÒìÐÔCTL,²¢ÔÚÃâÒß·À»¤ÖÐÆðÖØÒª×÷ÓÃ,ÇëÓ¦ÓÃÃâÒßѧÀíÂۺͷ½·¨,Éè¼ÆÒ»ÏµÍ³ÊµÑé,¼ÓÒÔ֤ʵ¡£
xKp4*[}m 4. Àý¾Ù¶þ¸ö½üÄêÀ´Ï¸°ûºÍ·Ö×ÓÃâÒßѧÑо¿ÖгöÏÖµÄеÄÈȵã,Çë·Ö±ðÆÀÊöÆäÑо¿ÒâÒå¡¢·¢Õ¹Ç÷ÊÆÒÔ¼°Ó¦ÓÃǰ¾°¡£